Login to Your Account

Other News To Note

Wednesday, June 13, 2012
• Tokai Pharmaceuticals Inc., of Cambridge, Mass., said the FDA granted fast-track designation for its lead candidate, galeterone (TOK-001), for metastatic castration-resistant prostate cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription